# Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy

Study · id `cardio:ct-nct01673204` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01673204](<https://clinicaltrials.gov/study/NCT01673204>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01673204

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 276 participants.

## Technical summary

Registry record NCT01673204. Randomized; double masking; primary purpose screening. Start 2012-10 (registry gives no type); primary completion 2014-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose screening
- Phase: Phase 4
- Enrolled: 276 participants (planned count; ClinicalTrials.gov record NCT01673204, source copy `cardio:ctgov-nct01673204-2014-02-13`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01673204, source copy `cardio:ctgov-nct01673204-2014-02-13`, retrieved 2026-10-26)
- Primary completion: 2014-04 (anticipated) (ClinicalTrials.gov record NCT01673204, source copy `cardio:ctgov-nct01673204-2014-02-13`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: South Korea (ClinicalTrials.gov record NCT01673204, source copy `cardio:ctgov-nct01673204-2014-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01673204-2014-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
- Condition: Diabetic Nephropathy
- Intervention (Drug): Calcitriol
- Intervention (Drug): Placebo
- Lead sponsor: Seoul National University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Seoul National University Hospital (`cardio:org-seoul-national-university-hospital`)

## Provenance

Content hash: b9cffe2a468f653eda08fb4d679f5a70091725beeee149d81e9c2cf6171c5d67
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
